Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology
- PMID: 17574305
- DOI: 10.1016/j.peptides.2007.04.026
Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology
Abstract
VIP and PACAP impact strongly on human pathophysiology. Their receptors are very promising targets for developing new drugs in the treatment of inflammatory and neurodegenerative diseases. This article reviews the present knowledge regarding VIP and PACAP receptors, i.e. VPAC1, VPAC2 and PAC1. This includes: (I) a critical review of instrumental peptide agonists and antagonists; (II) a survey of recent data regarding the structure of VPAC1 receptor and the docking of VIP in the receptor binding domain. Structural models for the VPAC2 and PAC1 receptor N-terminal ectodomains are also described; (III) A critical description of the two models of VPAC1 receptor activation in the general context of class II/family B G protein-coupled receptors.
Similar articles
-
Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.Int J Mol Med. 2002 Mar;9(3):233-43. Int J Mol Med. 2002. PMID: 11836629
-
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.Cancer Res. 2000 Jun 1;60(11):3105-12. Cancer Res. 2000. PMID: 10850463
-
Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.Clin Cancer Res. 2004 Dec 15;10(24):8235-42. doi: 10.1158/1078-0432.CCR-04-0939. Clin Cancer Res. 2004. PMID: 15623599
-
VPAC and PAC receptors: From ligands to function.Pharmacol Ther. 2009 Mar;121(3):294-316. doi: 10.1016/j.pharmthera.2008.11.006. Epub 2008 Dec 6. Pharmacol Ther. 2009. PMID: 19109992 Review.
-
VPAC1 receptor binding site: contribution of photoaffinity labeling approach.Neuropeptides. 2010 Apr;44(2):127-32. doi: 10.1016/j.npep.2009.11.008. Epub 2009 Dec 23. Neuropeptides. 2010. PMID: 20031208 Review.
Cited by
-
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.Br J Pharmacol. 2012 May;166(1):4-17. doi: 10.1111/j.1476-5381.2012.01871.x. Br J Pharmacol. 2012. PMID: 22289055 Free PMC article. Review.
-
The VPAC1 receptor: structure and function of a class B GPCR prototype.Front Endocrinol (Lausanne). 2012 Nov 16;3:139. doi: 10.3389/fendo.2012.00139. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 23162538 Free PMC article.
-
Pituitary adenylate cyclase-activating polypeptide deficiency enhances oxazolone-induced allergic contact dermatitis in mice.J Mol Neurosci. 2010 Nov;42(3):443-9. doi: 10.1007/s12031-010-9368-3. Epub 2010 Apr 23. J Mol Neurosci. 2010. PMID: 20414744
-
Diagnostic and Prognostic Value of PACAP in Multiple Myeloma.Int J Mol Sci. 2023 Jun 28;24(13):10801. doi: 10.3390/ijms241310801. Int J Mol Sci. 2023. PMID: 37445974 Free PMC article.
-
Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells.J Mol Neurosci. 2008 Nov;36(1-3):270-8. doi: 10.1007/s12031-008-9089-z. Epub 2008 Jul 8. J Mol Neurosci. 2008. PMID: 18607779
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
